Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147063 · ClinicalTrials.gov registry record · Phase 1
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
NCT06147063 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 243 participants.
The verdict
NCT06147063, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Interventions
- BIOLOGICAL AZD9838
- BIOLOGICAL Licensed mRNA vaccine
- BIOLOGICAL AZD6563
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06147063
The ClinicalTrials.gov registry entry for NCT06147063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AZD9838 is the first listed.
NCT06147063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06147063 about?
NCT06147063 is a clinical study titled "A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19". The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
What is the current status of trial NCT06147063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2023-11-27. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT06147063?
The interventions under investigation include: AZD9838 (BIOLOGICAL), Licensed mRNA vaccine (BIOLOGICAL), AZD6563 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06147063?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.